Mineralocorticoid Receptor Antagonists
"Mineralocorticoid Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.
| Descriptor ID |
D000451
|
| MeSH Number(s) |
D06.347.700 D27.505.696.399.450.600 D27.505.696.560.500.726.249
|
| Concept/Terms |
Mineralocorticoid Receptor Antagonists- Mineralocorticoid Receptor Antagonists
- Antagonists, Mineralocorticoid Receptor
- Receptor Antagonists, Mineralocorticoid
- Mineralocorticoid Antagonists
- Antagonists, Mineralocorticoid
- Aldosterone Receptor Antagonists
- Antagonists, Aldosterone Receptor
- Receptor Antagonists, Aldosterone
|
Below are MeSH descriptors whose meaning is more general than "Mineralocorticoid Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Mineralocorticoid Receptor Antagonists".
This graph shows the total number of publications written about "Mineralocorticoid Receptor Antagonists" by people in this website by year, and whether "Mineralocorticoid Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 14 | 11 | 25 |
| 2018 | 17 | 14 | 31 |
| 2019 | 8 | 5 | 13 |
| 2020 | 3 | 5 | 8 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mineralocorticoid Receptor Antagonists" by people in Profiles.
-
Tailoring the management of hypertension to comorbidities. Curr Opin Cardiol. 2021 07 01; 36(4):405-412.
-
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021 03 31; 20(1):75.
-
New Horizons: Does Mineralocorticoid Receptor Activation by Cortisol Cause ATP Release and COVID-19 Complications? J Clin Endocrinol Metab. 2021 03 08; 106(3):622-635.
-
Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19? J Cardiovasc Pharmacol. 2020 12 04; 77(3):323-331.
-
Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020 12; 22(12):2205-2215.
-
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions]. G Ital Cardiol (Rome). 2020 Oct; 21(10):750-756.
-
Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review. BMJ Open. 2020 09 14; 10(9):e040644.
-
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses. 2020 Oct; 143:110112.
-
Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease. Crit Care. 2020 06 08; 24(1):318.
-
Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. J Cardiovasc Pharmacol. 2020 06; 75(6):526-529.